Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11916226 | 0.81 | CYP2C19 (0.42) | CYP1A2LMNACYP2C19HTR1AADRA2A | |
| SCHEMBL11017179 | 0.78 | CYP1A2 (0.80) | CYP1A2ALOX15SMN1; SMN2ALDH1A1 | |
| SCHEMBL8182248 | 0.77 | LMNA (0.41) | CYP1A2LMNACYP2C19HTR1AADRA2A | |
| SCHEMBL16016862 | 0.77 | LMNA (0.41) | CYP1A2LMNACYP2C19HTR1AADRA2A | |
| SCHEMBL12475927 | 0.77 | LMNA (0.41) | CYP1A2LMNACYP2C19HTR1AADRA2A | |
| SCHEMBL376722 | 0.76 | LMNA (0.39) | CYP1A2LMNATDP1PDK2PDK4 | |
| SCHEMBL17302069 | 0.75 | CYP1A2 (0.52) | CYP1A2LMNACYP2C19HTR1AADRA2A | |
| SCHEMBL8008714 | 0.74 | CYP1A2 (0.52) | CYP1A2TDP1SMN1; SMN2HIF1AGAA | |
| SCHEMBL22119996 | 0.74 | LMNA (0.39) | CYP1A2LMNACYP2C19HTR1AADRA2A | |
| SCHEMBL9534057 | 0.73 | LMNA (0.35) | CYP1A2LMNACYP2C19HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160033250-A1 | CRYSTALLINE EXPLOSIVE MATERIAL | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2016-02-04 | — | — | US | claimed |
| US-11040922-B2 | Hydrogen peroxide solvates of energetic materials | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190002361-A1 | HYDROGEN PEROXIDE SOLVATES OF ENERGETIC MATERIALS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-01-03 | — | — | US | disclosed |
| EP-2658844-B1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI SA (FR) | 2016-10-26 | — | — | EP | disclosed |
| EP-2658844-B1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI SA (FR) | 2016-10-26 | — | — | EP | disclosed |
| US-20160033250-A1 | CRYSTALLINE EXPLOSIVE MATERIAL | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2016-02-04 | — | — | US | disclosed |
| US-9133168-B2 | Pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors | SANOFI (FR) | 2015-09-15 | — | — | US | disclosed |
| US-9133168-B2 | Pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors | SANOFI (FR) | 2015-09-15 | — | — | US | disclosed |
| US-9133168-B2 | Pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors | SANOFI (FR) | 2015-09-15 | — | — | US | disclosed |
| US-9096530-B2 | Crystalline explosive material | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-08-04 | — | — | US | disclosed |
| US-20130274253-A1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2013-10-17 | — | — | US | disclosed |
| US-20120305150-A1 | CRYSTALLINE EXPLOSIVE MATERIAL | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-12-06 | — | — | US | disclosed |
| WO-2012089633-A9 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2012-08-23 | — | — | WO | disclosed |
| WO-2012109354-A2 | CRYSTALLINE EXPLOSIVE MATERIAL | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012089633-A1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2012-07-05 | — | — | WO | disclosed |
| EP-0343752-B1 | Alkoxy-1,2,4-triazolo (1,5-c) pyrimidine-2-sulfonamides, process for their preparation and intermediates | DOWELANCO (US) | 1993-12-01 | — | — | EP | disclosed |
| US-5163995-A | For use with grassy crops and soybeans | DOWELANCO (US) | 1992-11-17 | — | — | US | disclosed |
| US-5010195-A | From 5-alkoxy-1,2,4-triazolo(1,5-c)pyrimidine | THE DOW CHEMICAL COMPANY (US) | 1991-04-23 | — | — | US | disclosed |
| WO-1989011782-A1 | ALKOXY-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE-2-SULFONAMIDES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES | THE DOW CHEMICAL COMPANY (US) | 1989-12-14 | — | — | WO | disclosed |
| EP-0343752-A1 | Alkoxy-1,2,4-triazolo (1,5-c) pyrimidine-2-sulfonamides, process for their preparation and intermediates | DowElanco (US) | 1989-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274253-A1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | TYMP, PIK3CA, PDPK1 | CYP1A2 3887/4885LMNA 3108/4885CYP2C19 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.